Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Analysts make mistakes, and often react after the fact, so it is important to take their advice with a grain of salt.

Buy Teva: A Recent Downgrade Is Overblown And Late To The Party

Amneal Pharmaceuticals

Lannett Company

Mylan

The industry drew the ire of 44 state attorneys general alleging widespread conspiracy to inflate drug prices.

Here's Why Generic-Drug Manufacturers Lost As Much As 43.2% in May

Shares jumped during Monday's session after Oppenheimer analysts upgraded the stock to Outperform with a $12 price target.

Teva Pharmaceutical Gets Reprieve After Analyst Upgrade

A detailed review of the 5/30 Bank of America - Merrill Lynch downgrade, which sets a $9 target price for Teva.

Teva: Suffering From A Bullish Downgrade

Analysts at Bank of America Merrill Lynch downgraded shares of Teva Pharmaceutical Industries Ltd.

Teva stock downgraded by Bank of America Merrill Lynch

Teva Pharmaceutical shares could remain under pressure given weak earnings, slowing revenues and unusual distribution signals.

Teva Pharmaceutical Shares Flag Red

Teva Pharmaceutical Industries Ltd shares have been under pressure since mid-May, when it was accused along with other generic companies for inflating the prices of generic drugs.

Teva's Legal Overhang Triggers UBS Downgrade, Near-Halving Of Price Target

An honest appraisal of the situation facing Teva.

Teva: One Of My Top 5 Picks

General Electric

Advanced Micro Devices

Options trading was buzzing in Teva Pharmaceuticals, Advanced Micro Devices, and General Electric on Tuesday. Here are the metrics that matter moving forward.

Wednesday’s Vital Data: Teva Pharmaceuticals, Advanced Micro Devices and General Electric

Teva (TEVA) plummets after settlement with the state of Oklahoma in a litigation related to its role in opioid epidemic, resulting in a rating downgrade.

Teva Settles With Oklahoma, Shares Fall Following Downgrade

Nutanix

Seadrill Ltd

Tough industry conditions took their toll on some stocks.

Why Teva Pharmaceutical Industries, Seadrill, and Nutanix Slumped Today

Gilead Sciences

NVIDIA

American Airlines

Nvidia, American Airlines, Teva, AMD and Gilead Sciences are our top stock trades to watch for Wednesday. See the charts here.

5 Top Stock Trades for Wednesday: GILD, NVDA, AMD

A larger-than-expected legal settlement might be a harbinger of things to come.

Here's Why Teva Pharmaceuticals Is Sinking Today

Teva crashed to a 19-year low Tuesday as a lawsuit alleging a generic drugs pricing racket continued to hammer the pharmaceutical company.

Pharma Giant Crashes To 19-Year Low On Generic Drugs Lawsuit

Teva Pharmaceutical Industries said on Sunday it had agreed an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that it and other drugmakers helped to fuel the U.S. opioid epidemic.

Teva Pharm to pay Oklahoma $85 million to settle opioid claims

Oklahoma has reached a $85 million settlement agreement with Israeli-based Teva Pharmaceutical Industries Ltd ahead of the start of a trial in a multibillion-dollar lawsuit over the opioid epidemic, the state's attorney general said on Sunday.

Oklahoma reaches $85 million settlement with Teva Pharmaceuticals ahead of trial

Teva Pharmaceutical and Mylan could be on the hook for billions in damages after a lawsuit accused pharmaceutical companies of colluding to fix generic drug prices, an analyst said Friday.

An Antitrust Lawsuit Could Cost Generic Pharmas Billions Of Dollars

Bausch Health Companies Inc

Which of these fallen stars has the more compelling comeback story?

Better Turnaround Play: Bausch Health Companies or Teva Pharmaceutical Industries

Teva Pharmaceutical shares continue to fall amid concerns about a lawsuit over alleged price fixing among generic drugmakers.

Teva Hits Fibonacci Support on Concerns Over Lawsuit

The recent news-based gap in TEVA is a buying opportunity providing an average 16% yearly ROI for brave buyers.

Teva: Undervalued Opportunity

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares were rocked this week after 44 different states filed a lawsuit against the company alleging Teva was among 20 different companies that conspired to manipulate and inflate drug prices.

Options Traders Making Big Long-Term Bets On Teva

Mallinckrodt PLC

Forty-four states have brought a lawsuit against the industry.

Here's Why Generic-Drug Manufacturers Were Down Monday

Teva is at the center of a drug pricing scandal, which only apparently is new.

Teva: Tarred And Feathered

Teva Pharmaceutical Industries tumbled after it and other companies were named in a price-fixing lawsuit.

Teva and others sued by 44 states

An alleged price-fixing scheme is the weighing on the drugmaker's shares today.

News for Teva Pharmaceutical Stock (TEVA)